BRPI0413276B8 - derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica - Google Patents
derivado de insulina, complexo de zinco do mesmo, e, composição farmacêuticaInfo
- Publication number
- BRPI0413276B8 BRPI0413276B8 BRPI0413276A BRPI0413276A BRPI0413276B8 BR PI0413276 B8 BRPI0413276 B8 BR PI0413276B8 BR PI0413276 A BRPI0413276 A BR PI0413276A BR PI0413276 A BRPI0413276 A BR PI0413276A BR PI0413276 B8 BRPI0413276 B8 BR PI0413276B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- zinc complex
- insulin derivative
- insulin
- amino group
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 5
- 239000004026 insulin derivative Substances 0.000 title abstract 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000011701 zinc Substances 0.000 title abstract 2
- 229910052725 zinc Inorganic materials 0.000 title abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301129 | 2003-08-05 | ||
| DKPA200301129 | 2003-08-05 | ||
| US49545103P | 2003-08-14 | 2003-08-14 | |
| US60/495,451 | 2003-08-14 | ||
| PCT/DK2004/000511 WO2005012347A2 (en) | 2003-08-05 | 2004-07-22 | Novel insulin derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0413276A BRPI0413276A (pt) | 2006-10-10 |
| BRPI0413276B1 BRPI0413276B1 (pt) | 2020-03-03 |
| BRPI0413276B8 true BRPI0413276B8 (pt) | 2021-05-25 |
Family
ID=34117520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413276A BRPI0413276B8 (pt) | 2003-08-05 | 2004-07-22 | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7615532B2 (en:Method) |
| EP (3) | EP2264065B1 (en:Method) |
| JP (1) | JP4463814B2 (en:Method) |
| KR (1) | KR101159559B1 (en:Method) |
| AU (2) | AU2004261353B2 (en:Method) |
| BE (2) | BE2013C035I2 (en:Method) |
| BR (1) | BRPI0413276B8 (en:Method) |
| CA (1) | CA2531988C (en:Method) |
| CY (5) | CY1113850T1 (en:Method) |
| FR (2) | FR13C0035I2 (en:Method) |
| HU (1) | HUS1300033I1 (en:Method) |
| IL (1) | IL172980A (en:Method) |
| LU (2) | LU92213I2 (en:Method) |
| MX (1) | MXPA06001283A (en:Method) |
| NO (5) | NO340925B1 (en:Method) |
| PL (1) | PL2107069T3 (en:Method) |
| RU (1) | RU2518460C2 (en:Method) |
| WO (1) | WO2005012347A2 (en:Method) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648933B1 (en) * | 2003-07-25 | 2009-06-17 | ConjuChem Biotechnologies Inc. | Long lasting insulin derivatives and methods thereof |
| KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| US8067362B2 (en) | 2005-02-02 | 2011-11-29 | Novo Nordisk As | Insulin derivatives |
| WO2006082205A1 (en) * | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
| JP4808785B2 (ja) * | 2005-12-28 | 2011-11-02 | ノボ・ノルデイスク・エー／エス | インスリン組成物および組成物の製造方法 |
| ES2387955T3 (es) * | 2006-02-27 | 2012-10-04 | Novo Nordisk A/S | Derivados de insulina |
| WO2007104736A2 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| EP2015722B1 (en) | 2006-04-28 | 2016-11-16 | Avent, Inc. | Antimicrobial site dressings |
| WO2007128815A1 (en) | 2006-05-09 | 2007-11-15 | Novo Nordisk A/S | Insulin derivative |
| CN101437849B (zh) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| EP2386572B1 (en) * | 2006-05-09 | 2015-07-08 | Novo Nordisk A/S | Insulin derivative |
| JP5097900B2 (ja) * | 2006-06-27 | 2012-12-12 | 独立行政法人物質・材料研究機構 | 有機酸又はこれらの誘導体の活性エステル体の製造方法 |
| ES2542146T3 (es) | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | Insulinas extendidas PEGiladas. |
| BRPI0717098B8 (pt) | 2006-09-22 | 2021-05-25 | Novo Nordisk As | análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação |
| WO2008132224A2 (en) | 2007-04-30 | 2008-11-06 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| CN101677944A (zh) * | 2007-06-01 | 2010-03-24 | 诺沃-诺迪斯克有限公司 | 稳定的非含水药物组合物 |
| US20110144010A1 (en) | 2007-06-01 | 2011-06-16 | Novo Nordisk A/S | Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier |
| JP5552046B2 (ja) * | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| AU2008288413B2 (en) * | 2007-08-15 | 2013-09-26 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| JP5721432B2 (ja) | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| CN101157725B (zh) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | 人胰岛素类似物的制备方法及用途 |
| CN101932601B (zh) | 2007-11-08 | 2016-08-03 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| PL2597103T3 (pl) | 2007-11-16 | 2017-04-28 | Novo Nordisk A/S | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
| ES2618073T3 (es) | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| CN102037008B (zh) | 2008-03-18 | 2016-08-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、酰化胰岛素类似物 |
| WO2010029159A1 (en) | 2008-09-12 | 2010-03-18 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| CN102202683A (zh) * | 2008-10-30 | 2011-09-28 | 诺沃-诺迪斯克有限公司 | 用少于每日一次的注射频率注射胰岛素来治疗糖尿病 |
| BRPI1007313A2 (pt) | 2009-01-23 | 2016-02-10 | Novo Nordisk As | derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso. |
| US8835379B2 (en) | 2009-10-30 | 2014-09-16 | Novo Nordisk A/S | Derivatives of CGRP |
| KR20120117013A (ko) * | 2010-01-12 | 2012-10-23 | 노보 노르디스크 에이/에스 | 인슐린 펩티드의 경구 투여를 위한 약학적 조성물 |
| ES2582590T3 (es) | 2010-02-16 | 2016-09-13 | Novo Nordisk A/S | Método de purificación |
| US9234192B2 (en) | 2010-02-16 | 2016-01-12 | Novo Nordisk A/S | Conjugated proteins |
| KR20130092972A (ko) | 2010-05-10 | 2013-08-21 | 노보 노르디스크 에이/에스 | 인슐린-아연 복합체의 제조 방법 |
| WO2011146973A1 (en) | 2010-05-25 | 2011-12-01 | Monash University | Insulin analogues |
| CN102933599A (zh) | 2010-06-23 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 包含额外的二硫键的人胰岛素 |
| EP2585484A1 (en) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
| US8853155B2 (en) | 2010-06-23 | 2014-10-07 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| CN103154024A (zh) | 2010-10-15 | 2013-06-12 | 诺沃—诺迪斯克有限公司 | 新型n末端修饰的胰岛素衍生物 |
| JP6049625B2 (ja) * | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| CN103167878A (zh) * | 2010-10-27 | 2013-06-19 | 诺沃—诺迪斯克有限公司 | 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病 |
| CN103249427A (zh) | 2010-12-14 | 2013-08-14 | 诺沃—诺迪斯克有限公司 | 速效胰岛素联合长效胰岛素 |
| WO2012110422A1 (en) | 2011-02-15 | 2012-08-23 | Novo Nordisk A/S | Long-acting il-1 receptor antagonists |
| CA2830974A1 (en) * | 2011-03-28 | 2012-10-04 | Jesper F. Lau | Novel glucagon analogues |
| US20140056953A1 (en) | 2011-04-14 | 2014-02-27 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| JP6058646B2 (ja) | 2011-06-15 | 2017-01-11 | ノヴォ ノルディスク アー／エス | 多置換インスリン |
| RU2017101333A (ru) * | 2011-09-23 | 2018-12-19 | Ново Нордиск А/С | Новые аналоги глюкагона |
| IN2014MN00933A (en:Method) * | 2011-12-15 | 2015-05-01 | Shanghai Hengrui Pharm Co Ltd | |
| JP2015502971A (ja) | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー／エス | Ｎ末端修飾インスリン誘導体 |
| ES2594303T3 (es) | 2012-04-11 | 2016-12-19 | Novo Nordisk A/S | Formulaciones de insulina |
| US20160031962A1 (en) * | 2012-04-20 | 2016-02-04 | Kleomenis K. Barlos | Solid phase peptide synthesis of insulin using side chain achored lysine |
| AU2013255880B2 (en) | 2012-05-01 | 2017-07-20 | Novo Nordisk A/S | Pharmaceutical composition |
| WO2014009316A1 (en) | 2012-07-09 | 2014-01-16 | Novo Nordisk A/S | Novel use of insulin derivatives |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| WO2014060447A1 (en) | 2012-10-17 | 2014-04-24 | Novo Nordisk A/S | Fatty acid acylated d-amino acids for oral peptide delivery |
| SG11201503524PA (en) | 2012-12-21 | 2015-06-29 | Sanofi Sa | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| CN105188736A (zh) * | 2013-03-20 | 2015-12-23 | 诺和诺德股份有限公司 | 胰岛素给药方案 |
| MX362275B (es) | 2013-04-18 | 2019-01-10 | Novo Nordisk As | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. |
| US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| US9896496B2 (en) | 2013-10-07 | 2018-02-20 | Novo Nordisk A/S | Derivative of an insulin analogue |
| FR3013049B1 (fr) | 2013-11-14 | 2015-11-13 | You-Ping Chan | Analogue de l'insuline glargine |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| KR20160114082A (ko) | 2014-02-18 | 2016-10-04 | 노보 노르디스크 에이/에스 | 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도 |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| EP3341402A1 (en) | 2015-08-25 | 2018-07-04 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| JP2018531901A (ja) | 2015-08-25 | 2018-11-01 | ノヴォ ノルディスク アー／エス | 新規インスリン誘導体及びその医学的使用 |
| EP3495384A4 (en) * | 2016-08-02 | 2020-02-26 | Jiangsu Hengrui Medicine Co., Ltd. | ACYLATED DERIVATIVE OF HUMAN INSULIN OR THE LIKE |
| WO2018096164A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| CN110099719A (zh) | 2016-11-28 | 2019-08-06 | 诺和诺德股份有限公司 | 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素 |
| JP7193455B2 (ja) | 2016-11-28 | 2022-12-20 | ノヴォ ノルディスク アー／エス | 心血管状態におけるインスリンデグルデク |
| MY200748A (en) | 2016-12-16 | 2024-01-13 | Novo Nordisk As | Insulin containing pharmaceutical compositions |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| US20210032307A1 (en) | 2018-02-09 | 2021-02-04 | Jiangsu Hengrui Medicine Co., Ltd. | Codon optimized precursor gene and signal peptide gene of human insulin analogue |
| US20210198311A1 (en) | 2018-05-24 | 2021-07-01 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preparing precursor of recombinant human insulin or analogue thereof |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| JP7410891B2 (ja) | 2018-06-26 | 2024-01-10 | ノボ・ノルデイスク・エー／エス | 基礎インスリン滴定のための投与推奨を提供するシステム |
| KR102666154B1 (ko) | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
| KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
| KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
| WO2021009027A1 (en) | 2019-07-12 | 2021-01-21 | Novo Nordisk A/S | High concentration insulin formulation |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN114901682B (zh) | 2019-12-30 | 2024-04-16 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| BR112022022885A2 (pt) | 2020-05-15 | 2022-12-20 | Lilly Co Eli | Compostos de insulina acilada de ação prolongada |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| US20250000948A1 (en) | 2021-11-15 | 2025-01-02 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| CN118574842A (zh) | 2022-01-28 | 2024-08-30 | 甘李药业股份有限公司 | 酰化胰岛素 |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| WO2025104600A1 (en) * | 2023-11-15 | 2025-05-22 | Ambio, Inc. | Insulin analogs for the treatment of human metabolic disorder and disease |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1212679B (de) | 1957-08-03 | 1966-03-17 | Novo Terapeutisk Labor As | Verfahren zur Herstellung von Insulinloesungen |
| GB1042194A (en) | 1962-04-30 | 1966-09-14 | Olin Mathieson | Insulin preparations |
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3868358A (en) | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
| FI78616C (fi) | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| DE3827533A1 (de) | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
| WO1990007522A1 (en) | 1988-12-23 | 1990-07-12 | Novo Nordisk A/S | Human insulin analogues |
| PT93057B (pt) | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| EP0506792B1 (en) | 1989-12-21 | 1995-05-17 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
| DK45590D0 (en:Method) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
| JP3193398B2 (ja) | 1991-07-23 | 2001-07-30 | サンデン株式会社 | ショ−ケ−ス |
| DE10399015I1 (de) | 1991-12-20 | 2012-05-03 | Novo Nordisk As | Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| EP0792290B1 (en) * | 1993-09-17 | 2001-08-29 | Novo Nordisk A/S | Acylated insulin |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| AU3562195A (en) | 1994-10-04 | 1996-04-26 | Novo Nordisk A/S | Preparations containing aspb28 human insulin and nicotinamide |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5830999A (en) | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| US6251856B1 (en) * | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| JP3872105B2 (ja) | 1995-03-17 | 2007-01-24 | ノボ ノルディスク アクティーゼルスカブ | インスリン誘導体 |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5898267A (en) * | 1996-04-10 | 1999-04-27 | Mcdermott; Kevin | Parabolic axial lighting device |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| DE69731105T2 (de) | 1996-07-11 | 2005-11-17 | Novo Nordisk A/S | Verfahren zur selektiven acetylierung |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| ATE264871T1 (de) | 1996-07-26 | 2004-05-15 | Aventis Pharma Gmbh | Insulinderivate mit erhöhter zinkbindung |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| EP1005490B1 (en) * | 1997-03-20 | 2006-03-29 | Novo Nordisk A/S | Zinc free insulin crystals for use in pulmonary compositions |
| JP2001518915A (ja) | 1997-03-20 | 2001-10-16 | ノボ ノルディスク アクティーゼルスカブ | インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法 |
| DE69806362T2 (de) | 1997-03-20 | 2003-01-30 | Novo Nordisk A/S, Bagsvaerd | Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält |
| US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| EP1283051B1 (en) | 1997-06-13 | 2006-06-14 | Eli Lilly And Company | Stable insulin formulations |
| US6451762B1 (en) | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| US20020155994A1 (en) | 1997-10-24 | 2002-10-24 | Svend Havelund | Aggregates of human insulin derivatives |
| PT1025125E (pt) * | 1997-10-24 | 2003-11-28 | Novo Nordisk As | Derivativos agregados da insulina humana |
| AU1111799A (en) | 1997-10-24 | 1999-05-17 | Eli Lilly And Company | Fatty acid-acylated insulin analogs |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| US6531448B1 (en) | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
| WO1999034821A1 (en) | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| UA65636C2 (uk) | 1998-10-16 | 2004-04-15 | Ново Нордіск А/С | Стабільні концентровані препарати інсуліну для доставки через легені |
| US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| ATE365052T1 (de) | 1999-02-22 | 2007-07-15 | Univ Connecticut | Neue albuminfreie faktor viii formulierungen |
| AU4450700A (en) | 1999-04-27 | 2000-11-10 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| JP5562510B2 (ja) | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー／エス | 修飾ｇｌｐ−１の安定な処方剤 |
| SK2432004A3 (sk) | 2001-12-20 | 2005-04-01 | Eli Lilly And Company | Inzulínová zlúčenina s protrahovaným účinkom |
| US8003605B2 (en) | 2002-03-13 | 2011-08-23 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| EP1506230B1 (en) | 2002-05-07 | 2011-01-19 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
| US20050232899A1 (en) | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| US20040002451A1 (en) | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| KR100615389B1 (ko) | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
| JP2006504772A (ja) | 2002-10-29 | 2006-02-09 | アルザ・コーポレーション | 安定化された固体ポリペプチド粒子 |
| US20040138099A1 (en) | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| BRPI0407303A (pt) | 2003-02-07 | 2006-02-07 | Ajinomoto Kk | Composição farmacêutica |
| CN100422328C (zh) | 2003-02-19 | 2008-10-01 | 诺瓦提斯公司 | 在人转移性肿瘤细胞中表达的糖蛋白抗原sima135 |
| KR20060014027A (ko) | 2003-03-04 | 2006-02-14 | 더 테크놀로지 디벨로프먼트 컴퍼니 리미티드 | 지속성의 주사용 인슐린 조성물 및 그 제조방법 및사용방법 |
| ES2382157T3 (es) | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
| US20050054818A1 (en) | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
| PT2107069E (pt) | 2003-08-05 | 2013-04-23 | Novo Nordisk As | Novos derivados de insulina |
| KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| ES2574581T3 (es) | 2003-08-14 | 2016-06-20 | Novo Nordisk Health Care Ag | Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII |
| WO2005021022A2 (en) | 2003-09-01 | 2005-03-10 | Novo Nordisk A/S | Stable formulations of peptides |
| ES2229931B1 (es) | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
| EP1687428A1 (en) | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Processes for making acylated insulin |
| CA2551510C (en) | 2003-12-23 | 2013-07-30 | Pharmacia Corporation | Stable growth hormone liquid formulation |
| PT1740154E (pt) | 2004-03-12 | 2009-09-11 | Biodel Inc | Composições de insulina com absorção melhorada |
| UA93349C2 (ru) | 2004-06-01 | 2011-02-10 | Эйрэс Трейдинг C.A. | Способ стабилизации мономерного белка интерферона |
| JP4971160B2 (ja) | 2004-08-12 | 2012-07-11 | シェーリング コーポレイション | 安定するｐｅｇ化インターフェロン処方物 |
| ES2395035T3 (es) | 2004-08-17 | 2013-02-07 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de la IL-1 |
| ES2575984T3 (es) | 2004-11-12 | 2016-07-04 | Novo Nordisk A/S | Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal |
| JP4874989B2 (ja) | 2004-11-22 | 2012-02-15 | ノヴォ ノルディスク アー／エス | 可溶性で安定なインスリン含有調合物 |
| US20060188555A1 (en) | 2005-01-21 | 2006-08-24 | Micheal Cormier | Therapeutic peptide formulations with improved stability |
| US8067362B2 (en) * | 2005-02-02 | 2011-11-29 | Novo Nordisk As | Insulin derivatives |
| JP4808785B2 (ja) | 2005-12-28 | 2011-11-02 | ノボ・ノルデイスク・エー／エス | インスリン組成物および組成物の製造方法 |
| ES2387955T3 (es) | 2006-02-27 | 2012-10-04 | Novo Nordisk A/S | Derivados de insulina |
| EP2012817A2 (en) | 2006-04-12 | 2009-01-14 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| EP2386572B1 (en) | 2006-05-09 | 2015-07-08 | Novo Nordisk A/S | Insulin derivative |
| JP5552046B2 (ja) | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| PL2597103T3 (pl) | 2007-11-16 | 2017-04-28 | Novo Nordisk A/S | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
-
2004
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/ko not_active Expired - Lifetime
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/pt active IP Right Grant
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/es active IP Right Grant
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
- 2004-07-22 PL PL09165072T patent/PL2107069T3/pl unknown
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en active Application Filing
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/ja not_active Expired - Lifetime
-
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/no active Protection Beyond IP Right Term
-
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/ru active
-
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
-
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
-
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/el unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/fr unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/xx unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/fr active Active
- 2013-07-04 CY CY2013027C patent/CY2013027PI1/el unknown
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/fr active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI1/el unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/hu unknown
-
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
-
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/no unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/no unknown
-
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/el unknown
-
2024
- 2024-01-16 NO NO2024004C patent/NO2024004I1/no unknown
- 2024-01-16 NO NO2024003C patent/NO2024003I1/no unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413276B8 (pt) | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica | |
| SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
| WO2008081701A1 (ja) | Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 | |
| NZ591497A (en) | A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment | |
| EP2390265A3 (en) | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | |
| BR0315047A (pt) | Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto | |
| BRPI0717098B8 (pt) | análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação | |
| AR061500A1 (es) | Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes | |
| CY1112241T1 (el) | Θραυσματα πεπτιδιου για διεγερση συνθεσης πρωτεϊνων εξωκυτταρικης μητρας | |
| DE60314495D1 (de) | Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern | |
| ATE513853T1 (de) | Peptide und peptidderivate sowie pharmazeutische zusammensetzungen, die diese enthalten | |
| BRPI0511421A (pt) | composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo | |
| CO6231039A2 (es) | Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas | |
| ATE506957T1 (de) | Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen | |
| AR055179A1 (es) | Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas | |
| NZ601142A (en) | Composition for improving brain function and method for improving brain function | |
| BRPI0513858A (pt) | compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa | |
| MX363119B (es) | Composicion farmaceutica. | |
| ATE443722T1 (de) | Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung | |
| BRPI0621347B8 (pt) | composição farmacêutica para aumentar a produção de eritrócitos e para o tratamento de anemia | |
| EA200700976A1 (ru) | Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой | |
| UY29498A1 (es) | Derivados de aminoácidos | |
| MX2009002962A (es) | Peptidos antibacterianos y antivirales de actinomadura namibiensis. | |
| BRPI0512503A (pt) | composição que compreende ácido lático e lactoferrina | |
| ATE427956T1 (de) | Ckrox-peptide und ihre analoge zur behandlung von hautalterung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI NO 52402.001245/2022-49 ORIGEM: 13A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1087251-24.2021.4.01.3400 SUBJUDICE AUTOR: NOVO NORDISK A/S E NOVO NORDISK FARMACEUTICA DO BRASIL LTDA. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL |